Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–11. PMID: 33538338. https://dx.doi.org/10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Pesola G, Martelli V, Sobrero AF. Adjuvant Chemotherapy for Stage II Colon Cancer. Cancers (Basel). 2020;12 PMID: 32927771. doi:10.3390/cancers12092584.
   Google Scholar
• Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, Yoshino T, Taieb J, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291–1305. PMID: 32702383. doi:10.1016/j.annonc.2020.06.022.
   PubMed Web of Science ®Google Scholar
• Costas-Chavarri A, Nandakumar G, Temin S, Lopes G, Cervantes A, Cruz Correa M, Engineer R, Hamashima C, Ho GF, Huitzil FD, et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. J Glob Oncol. 2019;5:1–19. PMID: 30802158. doi:10.1200/JGO.18.00214.
   Web of Science ®Google Scholar
• Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol. 2021;32:1496–1510. PMID: 34411693. doi:10.1016/j.annonc.2021.08.1752.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology: colon cancer. Available online: 2022. [accessed 2022]. Version 1; https://wwwnccn.org/professionals/physician_gls/pdf/colon_blocks.pdf
   Google Scholar
• Babcock BD, Aljehani MA, Jabo B, Choi AH, Morgan JW, Selleck MJ, Luca F, Raskin E, Reeves ME, Garberoglio CA, et al. High-Risk Stage II colon cancer: not all risks are created equal. Ann Surg Oncol. 2018;25:1980–1985. PMID: 29675762. doi:10.1245/s10434-018-6484-8.
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, Hamilton SR. Path toward prognostication and prediction: an evolving matrix. J Clin Oncol. 2011;29:4599–4601. PMID: 22067398. doi:10.1200/JCO.2011.37.8646.
   PubMed Web of Science ®Google Scholar
• O’Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–3388. PMID: 21788561. doi:10.1200/JCO.2010.34.3426.
   PubMed Web of Science ®Google Scholar
• Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–2029. PMID: 18083404. doi:10.1016/S0140-6736(07)61866-2.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020. PMID: 32753728 10.1038/s41568-020-0285-7
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. PMID: 22419253.
   PubMed Web of Science ®Google Scholar
• Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: colon cancer and beyond. Clin Cancer Res. 2020;26:332–339. PMID: 31413009. doi:10.1158/1078-0432.CCR-18-1851.
   PubMed Web of Science ®Google Scholar
• Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–2139. PMID: 29754777. doi:10.1016/S0140-6736(18)30789-X.
   PubMed Web of Science ®Google Scholar
• Galon J, Hermitte F, Mlecnik B, Marliot F, Bifulco CB, Lugli A, Nagtegaal ID, Hartmann A, Van den Eynde M, Roehrl MHA, et al. Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinicopathological features for whom adjuvant treatment may be avoided. J Clin Oncol. 2019;37. PMID: WOS:000489107600493. doi:10.1200/JCO.2019.37.4_suppl.487.
   Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. PMID: 16371631. N Engl J Med. 2005;353:2654–2666.
   PubMed Web of Science ®Google Scholar
• Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, Li L, Ding P, Zhao Q, Li Y, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. J Hematol Oncol. 2021;14:80. PMID: 34001194. doi:10.1186/s13045-021-01089-z.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bifulco C, Marliot F, Bindea G, Lee JJ, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, et al. Multicenter international SITC study of the consensus Immunoscore for the prediction of survival and response to chemotherapy in Stage III colon cancer. J Clin Oncol. 2020;38(31):3638–3651. PMID: 32897827. doi:10.1200/JCO.19.03205.
   PubMed Web of Science ®Google Scholar
• Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31:921–929. PMID: 32294529. doi:10.1016/j.annonc.2020.03.310.
   PubMed Web of Science ®Google Scholar
• Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2022;28:507–517. PMID: 34625408. doi:10.1158/1078-0432.CCR-21-2404.
   PubMed Web of Science ®Google Scholar
• Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu H-T, Tin AS, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA oncol. 2019;5:1124–1131. PMID: 31070691. doi:10.1001/jamaoncol.2019.0528.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261–2272. PMID: 35657320. doi:10.1056/NEJMoa2200075.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA oncol. 2019;5:1710–1717. PMID: 31621801. doi:10.1001/jamaoncol.2019.3616.
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra392. PMID: 27384348. doi:10.1126/scitranslmed.aaf6219.
   Web of Science ®Google Scholar
• Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, et al. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. Cancers (Basel). 2022;14(18): 4346. PMID: 36139506. doi: 10.3390/cancers14184346.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1:179–188. PMID: 22720239. doi:10.4161/onci.1.2.19026.
   PubMed Web of Science ®Google Scholar
• Naidoo M, Gibbs P, Tie J. ctDNA and adjuvant therapy for colorectal cancer: time to re-invent our treatment paradigm. Cancers (Basel). 2021;13 PMID: 33477814. doi:10.3390/cancers13020346.
   PubMed Web of Science ®Google Scholar
• Taieb J, Karoui M, Basile D. How I treat stage II colon cancer patients. ESMO Open. 2021;6:100184. PMID: 34237612. doi:10.1016/j.esmoop.2021.100184.
   PubMedGoogle Scholar
• Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology. 2014;3:e27456. PMID: 24800163. doi:10.4161/onci.27456.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. PMID: 17008531. Science. 2006;313:1960–1964.
   PubMed Web of Science ®Google Scholar
• Galon J, Sudarshan C, Ito S, Finbloom D, O’Shea JJ. IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J Immunol. 1999;162:7256–7262. PMID: 10358173.
   PubMed Web of Science ®Google Scholar
• Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23:876–887. PMID: 35636444. doi:10.1016/s1470-2045(22)00274-1.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2013;2:e23510. PMID: 23687621. doi:10.4161/onci.23510.
   PubMed Web of Science ®Google Scholar
• Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, et al. ctDNA applications and integration in colorectal cancer: an NCI colon and rectal-anal task forces whitepaper. Nat Rev Clin Oncol. 2020;17:757–770. PMID: 32632268. doi:10.1038/s41571-020-0392-0.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med. 2013;11:54. PMID: 23452415. doi:10.1186/1479-5876-11-54.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–340. PMID: 21461991. doi:10.1007/s00281-011-0264-x.
   PubMed Web of Science ®Google Scholar